Mount Sinai won a five-year, $20.7 million agreement to develop its VITAL vaccine platform, with an intranasal H5N1 mRNA prototype designed to target antigen expression to respiratory immune cells. The program is positioned as a next-generation approach to respiratory viral prevention. The project’s emphasis on intranasal delivery aligns with the goal of priming local mucosal immunity while maintaining mRNA flexibility for rapid updates. The funding accelerates platform development ahead of prototype testing and potential later-stage translation. For the industry, the announcement is notable as a clear infrastructure investment in a delivery-and-immunology concept rather than a single product. It may influence how future influenza-like pandemic readiness programs allocate money across platforms. The work also suggests that respiratory-focused antigen targeting remains a priority design axis for mRNA vaccines.